How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Idexx Laboratories (IDXX) ten years ago? It may not have been easy to hold on to IDXX for all that time, but if you did, how much would your investment be worth today?
Idexx Laboratories' Business In-Depth
With that in mind, let's take a look at Idexx Laboratories' main business drivers.
Headquartered in Westbrook, ME, IDEXX Laboratories, Inc. is a developer, manufacturer and distributor of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company also sells a series of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
IDEXX operates through four segments:
Companion Animal Group (CAG) (91.7% of revenues in 2024, up 1.0% from 2023): This segment provides veterinarians with diagnostic capabilities and information management solutions that enhance the health and well-being of pets. The complementary nature of these products and services provides a unique competitive advantage known as the IDEXX Diagnostic Advantage, providing vets with the tools and services necessary to offer advanced veterinary medical care.
Water (4.7%, up 2.2%): Through this segment, IDEXX provides innovative testing solutions for easy, rapid and accurate detection and quantification of various microbiological parameters in water, helping ensure water safety for people worldwide.
Livestock, Poultry and Dairy (LPD) (3.1%, down 6.0%): Within this segment, IDEXX provides diagnostic tests and related instrumentation required to manage the health status of livestock and poultry to improve bovine reproductive efficiency and ensure the quality and safety of milk and food. These products are purchased by the government and private laboratories that provide testing services to cattle, swine and poultry veterinarians, producers and processors.
Other (0.4%, down 20.0%): The company’s OPTI Medical operating segment has been combined and presented with the remaining pharmaceutical product line and the out-licensing arrangements in an ‘Other’ category, primarily because they do not meet the quantitative or qualitative thresholds for reportable segments.
Bottom Line
Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Idexx Laboratories, ten years ago, you're likely feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in December 2015 would be worth $10,653.46, or a gain of 965.35%, as of December 1, 2025, and this return excludes dividends but includes price increases.
Compare this to the S&P 500's rally of 227.69% and gold's return of 279.23% over the same time frame.
Analysts are forecasting more upside for IDXX too.
IDEXX's robust strategic execution is highlighted by new business wins, high customer retention levels and solid net price realization. The company designs its commercial strategies around regional dynamics, using its strong Reference Laboratory networks and tailored innovation approach. Notably, CAG Diagnostics recurring revenues is seeing accelerating gains across major regions. IDEXX is building out its commercial expansion in markets with the strongest customer readiness and growth potential. The company's software solutions are also facilitating growth by enhancing clinic workflows and promoting greater utilization of diagnostics. Meanwhile, a debt-burdened balance sheet raises concern. IDEXX's wide global presence makes it vulnerable to currency fluctuations. Meanwhile, broader macroeconomic issues are slowing its operations.
Over the past four weeks, shares have rallied 19.60%, and there have been 7 higher earnings estimate revisions in the past two months for fiscal 2025 compared to none lower. The consensus estimate has moved up as well.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
